Phase 3 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing to take part and agree to sign a consent form.
- You are 18 years of age or older (any gender can apply).
- You have been diagnosed with liver cancer (hepatocellular carcinoma), confirmed by a tissue sample, cell sample, or medical imaging.
- Your liver cancer falls within certain defined stages of severity — specifically stages Ib (a single tumor 8 cm or larger), IIa, IIb, or IIIa, with some exceptions around how the cancer has spread (confirm with trial site for exact staging details).
- Your liver is functioning reasonably well, based on a scoring system called Child-Pugh (you must score 6 points or fewer, which means "Grade A").
- You are generally well enough to carry out daily activities, based on a standard performance scale (scored 0 or 1 out of 5).
Who may not be able to join:
- You have a specific type of liver or bile duct cancer other than standard hepatocellular carcinoma (such as cholangiocarcinoma or mixed cell carcinoma).
- You have had, or currently have, another active cancer (other than liver cancer) within the past 5 years.
- You currently have, or have been diagnosed with, a lung condition involving scarring or inflammation of lung tissue.
- You have an active autoimmune disease (where your immune system attacks your own body), or a history of one that could come back.
- You have an active infection, an unexplained fever of 38.5°C or higher in the week before joining, or an unusually high white blood cell count.
- You have a condition that weakens your immune system, such as HIV.
- You are known to be allergic to monoclonal antibody medications, anti-cancer drugs that target blood vessel growth, or their ingredients.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xuehao Wang, professor, The First Affiliated Hospital with Nanjing Medical University
Phone: 86-025-68303211
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
2 year event-free survival（2y-EFS）
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.